Pharmaceutical firms may no longer have to appear in courts in case of “certain minor contraventions” and instead, they can ...

Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more ...

Hyderabad based HRV Pharma, India’s ‘first virtual pharmaceutical company’, started off as a B2B match maker between Indian ...

Enforcement alone is failing. A new governance model—integrating forensic science, community care, and real-time intelligence ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

UnitedHealth ended last fiscal year with more than $75 billion in cash, cash equivalents, available-for-sale debt securities, ...

Sustainable Growth Advisers (SGA), an investment management company, released its third-quarter investor letter for its “U.S.

Given the complexity of our sexual health, it’s probably helpful to stop hoping there will be a single magic pill or potion ...

Learn more about whether Glaukos Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In the past year or so, health influencers — and a lot of women on social media — have talked up testosterone therapy as a kind of perimenopausal panacea. They promise boundless energy, crisper ...